Novo Nordisk A/S regained its location as a more valuable public company in Europe, and surpassed the SAP SE software developer.
The shares in the Danish pharmaceutical maker increased by up to 2.3 % on Friday after Novo said it was planning to push its experimental treatment to manage Amycretin weight to the development of the late stage after reactions from the regulatory authorities.
The market value of Novo was 365 billion dollars from 10:20 am in Copenhagen. This compares with 364.3 billion dollars to SAP, according to the data collected by Bloomberg.
NOVO has suffered from a series of setbacks since it reached a record level in June last year, including the results of clinical disappointing trials to treat experimental obesity and the installation competition from its opponent ELI Lilly & Co. The pharmaceutical maker decided last month to replace the CEO Lars Faragard Georgessen.
The shares were strengthened this week after the Financial Times report on the management assets of Parvus Asset ManagementCategoryIn Novo, hoping to influence the appointment of the new CEO of the pharmaceutical maker.
This story was originally shown on Fortune.com
https://fortune.com/img-assets/wp-content/uploads/2025/06/GettyImages-2197221612-e1749805697913.jpg?resize=1200,600
Source link